This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / VistaGen Therapeutics Class Action Lawsuit
Business class action lawsuit

VistaGen Therapeutics Class Action Lawsuit

Analysis based on 16 articles · First reported Jan 29, 2026 · Last updated Feb 05, 2026

Sentiment
-20
Attention
2
Articles
16
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the failure of VistaGen Therapeutics' Phase 3 trial, leading to a significant drop in its stock price. This event highlights the risks associated with pharmaceutical development and can cause investor caution in the biotechnology sector.

Pharmaceuticals Biotechnology
Event Summary

VistaGen Therapeutics is facing a class action securities lawsuit initiated by Levi & Korsinsky on behalf of investors. The lawsuit alleges securities fraud between April 1, 2024, and December 16, 2025. This stems from VistaGen Therapeutics' overwhelmingly positive statements regarding its Phase 3 PALISADE-3 trial for fasedienol, an investigational pherine candidate for social anxiety disorder. On December 17, 2025, VistaGen Therapeutics announced that the trial did not achieve its primary endpoint, resulting in an over 80% decline in its common stock price from $4.36 to $0.86 per share. Investors have until March 16, 2026, to request to be appointed as lead plaintiff.

Key Actions
100 VistaGen Therapeutics announced Phase 3 trial failure for fasedienol
95 VistaGen Therapeutics stock price declined dramatically
90 Levi & Korsinsky notified investors of class action securities lawsuit VistaGen Therapeutics
Entities Involved
stock
VistaGen Therapeutics
VistaGen Therapeutics is facing a class action securities lawsuit due to alleged securities fraud. The lawsuit stems from the failure of its Phase 3 PALISADE-3 trial for fasedienol, which led to a significant drop in its stock price.
Importance 100 Sentiment -80
priv
Levi & Korsinsky
Levi & Korsinsky, a law firm, is notifying investors about a class action securities lawsuit against VistaGen Therapeutics. The firm is actively seeking lead plaintiffs for the lawsuit.
Importance 70 Sentiment 50
per
Joseph E. Levi
Joseph E. Levi, an attorney at Levi & Korsinsky, is a contact person for VistaGen Therapeutics investors interested in the class action lawsuit.
Importance 40 Sentiment 30
exch
Nasdaq
VistaGen Therapeutics is listed on Nasdaq, which is the exchange where its stock price declined dramatically following the trial results.
Importance 10 Sentiment 0
Relationships
Joseph E. Levi related ↔ Levi & Korsinsky
VistaGen Therapeutics related ↔ Levi & Korsinsky
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.